$ACTC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Ocata Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Ocata Therapeutics, Inc.. Get notifications about new insider transactions in Ocata Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 8.49 | 76,666 | 650,894 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 8.49 | 35,334 | 299,986 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 6.20 | 12,858 | 79,720 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 15.70 | 150,000 | 2,355,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 19.50 | 17,834 | 347,763 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 9.80 | 53,500 | 524,300 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 21.00 | 40,000 | 840,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | U | 8.50 | 231,509 | 1,967,827 | 0 | 231.5 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Myles Edward H | COO & CFO | Option Exercise | D | 8.49 | 112,000 | 950,880 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Myles Edward H | COO & CFO | Option Exercise | D | 7.78 | 140,000 | 1,089,200 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Myles Edward H | COO & CFO | Sell | U | 8.50 | 56,000 | 476,000 | 0 | 56 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | D | 8.36 | 5,000 | 41,800 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | D | 6.39 | 5,000 | 31,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | D | 6.17 | 5,000 | 30,850 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | D | 5.79 | 5,000 | 28,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | D | 9.00 | 5,000 | 45,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | D | 10.37 | 417 | 4,324 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Sell | U | 8.50 | 21,417 | 182,045 | 0 | 21.4 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LEVY BRIAN | Director | Option Exercise | D | 8.36 | 5,000 | 41,800 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LEVY BRIAN | Director | Sell | U | 8.50 | 12,500 | 106,250 | 0 | 12.5 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Jooste H Le Roux | SVP of Bus Developm ... | Option Exercise | D | 6.32 | 75,000 | 474,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Jooste H Le Roux | SVP of Bus Developm ... | Sell | U | 8.50 | 25,000 | 212,500 | 0 | 25 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | D | 8.36 | 5,000 | 41,800 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | D | 6.39 | 5,000 | 31,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | D | 6.17 | 5,000 | 30,850 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | D | 5.79 | 5,000 | 28,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | D | 9.00 | 5,000 | 45,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | D | 18.50 | 5,000 | 92,500 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | D | 13.50 | 500 | 6,750 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Sell | U | 8.50 | 15,530 | 132,005 | 0 | 15.5 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Sell | U | 8.50 | 15,530 | 132,005 | 0 | 15.5 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Sell | U | 8.50 | 252,206 | 2,143,751 | 0 | 252.2 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Anglade Eddy | Chief Medical Offic ... | Option Exercise | D | 8.49 | 112,000 | 950,880 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Anglade Eddy | Chief Medical Offic ... | Option Exercise | D | 8.99 | 100,000 | 899,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Anglade Eddy | Chief Medical Offic ... | Sell | U | 8.50 | 56,000 | 476,000 | 0 | 56 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 8.36 | 5,000 | 41,800 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 6.39 | 10,000 | 63,900 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 7.94 | 100,000 | 794,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 6.17 | 10,000 | 61,700 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 6.00 | 1,250 | 7,500 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 5.79 | 5,000 | 28,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 8.00 | 3,621 | 28,968 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Sell | U | 8.50 | 31,000 | 263,500 | 0 | 31 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | D | 8.36 | 5,000 | 41,800 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | D | 6.39 | 5,000 | 31,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | D | 6.39 | 5,000 | 31,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | D | 6.17 | 5,000 | 30,850 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | D | 5.79 | 5,000 | 28,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | D | 9.00 | 834 | 7,506 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Sell | U | 8.50 | 21,834 | 185,589 | 0 | 21.8 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | D | 8.36 | 5,000 | 41,800 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | D | 6.39 | 5,000 | 31,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | D | 6.17 | 5,000 | 30,850 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | D | 5.79 | 5,000 | 28,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | D | 9.00 | 5,000 | 45,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | D | 20.00 | 20,000 | 400,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | D | 14.30 | 1,250 | 17,875 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Sell | U | 8.50 | 51,000 | 433,500 | 0 | 51 K to 0 (-100.00 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Wotton Paul K | President and CEO | Option Exercise | D | 6.55 | 300,000 | 1,965,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Wotton Paul K | President and CEO | Sell | U | 8.50 | 277,500 | 2,358,750 | 0 | 277.5 K to 0 (-100.00 %) |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | A | 8.36 | 5,000 | 41,800 | 5,000 | |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 1,250 | 0 | 21,417 | 20.2 K to 21.4 K (+6.20 %) |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 8.36 | 5,000 | 41,800 | 5,000 | |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 1,250 | 0 | 252,206 | 251 K to 252.2 K (+0.50 %) |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | A | 8.36 | 5,000 | 41,800 | 5,000 | |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 1,250 | 0 | 52,250 | 51 K to 52.3 K (+2.45 %) |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 8.36 | 10,000 | 83,600 | 10,000 | |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 31,000 | 28.5 K to 31 K (+8.77 %) |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | LEVY BRIAN | Director | Option Exercise | A | 8.36 | 5,000 | 41,800 | 5,000 | |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | LEVY BRIAN | Director | Grant | A | 0.00 | 1,250 | 0 | 12,500 | 11.3 K to 12.5 K (+11.11 %) |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | A | 8.36 | 5,000 | 41,800 | 5,000 | |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 1,250 | 0 | 21,834 | 20.6 K to 21.8 K (+6.07 %) |
| Nov 10 2015 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 8.36 | 10,000 | 83,600 | 196,509 | 206.5 K to 196.5 K (-4.84 %) |
| Nov 10 2015 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 8.36 | 10,000 | 83,600 | 206,509 | 216.5 K to 206.5 K (-4.62 %) |
| Nov 10 2015 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 8.25 | 15,000 | 123,750 | 216,509 | 231.5 K to 216.5 K (-6.48 %) |
| Oct 01 2015 | ACTC | Ocata Therapeutics ... | LEVY BRIAN | Director | Grant | A | 0.00 | 1,250 | 0 | 11,250 | 10 K to 11.3 K (+12.50 %) |
| Oct 01 2015 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 1,250 | 0 | 20,167 | 18.9 K to 20.2 K (+6.61 %) |
| Oct 01 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 28,500 | 26 K to 28.5 K (+9.62 %) |
| Oct 01 2015 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 1,250 | 0 | 20,584 | 19.3 K to 20.6 K (+6.47 %) |
| Oct 01 2015 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 1,250 | 0 | 51,000 | 49.8 K to 51 K (+2.51 %) |
| Oct 01 2015 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 1,250 | 0 | 250,956 | 249.7 K to 251 K (+0.50 %) |
| Sep 10 2015 | ACTC | Ocata Therapeutics ... | LEVY BRIAN | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| Jul 31 2015 | ACTC | Ocata Therapeutics ... | Wotton Paul K | President and CEO | Payment of Exercise | F | 4.23 | 32,500 | 137,475 | 267,500 | 300 K to 267.5 K (-10.83 %) |
| Jul 02 2015 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 1,250 | 0 | 49,750 | 48.5 K to 49.8 K (+2.58 %) |
| Jul 02 2015 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 1,250 | 0 | 19,334 | 18.1 K to 19.3 K (+6.91 %) |
| Jul 02 2015 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 1,250 | 0 | 249,706 | 248.5 K to 249.7 K (+0.50 %) |
| Jul 02 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 26,000 | 23.5 K to 26 K (+10.64 %) |
| Jul 02 2015 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 1,250 | 0 | 18,917 | 17.7 K to 18.9 K (+7.08 %) |
| Apr 01 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 23,500 | 21 K to 23.5 K (+11.90 %) |
| Apr 01 2015 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 1,250 | 0 | 206,358 | 205.1 K to 206.4 K (+0.61 %) |
| Apr 01 2015 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 1,250 | 0 | 18,084 | 16.8 K to 18.1 K (+7.43 %) |
| Apr 01 2015 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 1,250 | 0 | 48,500 | 47.3 K to 48.5 K (+2.65 %) |
| Apr 01 2015 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 1,250 | 0 | 17,667 | 16.4 K to 17.7 K (+7.61 %) |
| Mar 09 2015 | ACTC | Ocata Therapeutics ... | Wotton Paul K | President and CEO | Grant | A | 0.00 | 10,000 | 0 | 310,000 | 300 K to 310 K (+3.33 %) |
| Jan 05 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 6.39 | 10,000 | 63,900 | 10,000 | |
| Jan 05 2015 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | A | 6.39 | 5,000 | 31,950 | 5,000 | |
| Jan 05 2015 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | A | 6.39 | 5,000 | 31,950 | 5,000 | |
| Jan 05 2015 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | A | 6.39 | 5,000 | 31,950 | 5,000 | |
| Jan 05 2015 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 6.39 | 5,000 | 31,950 | 5,000 | |
| Jan 02 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 21,000 | 18.5 K to 21 K (+13.51 %) |
| Jan 02 2015 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 1,250 | 0 | 205,108 | 203.9 K to 205.1 K (+0.61 %) |
| Jan 02 2015 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 1,250 | 0 | 16,834 | 15.6 K to 16.8 K (+8.02 %) |
| Jan 02 2015 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 1,250 | 0 | 47,250 | 46 K to 47.3 K (+2.72 %) |
| Jan 02 2015 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 1,250 | 0 | 16,417 | 15.2 K to 16.4 K (+8.24 %) |
| Nov 25 2014 | ACTC | Ocata Therapeutics ... | Jooste H Le Roux | Chief Commercial Of ... | Option Exercise | A | 6.32 | 75,000 | 474,000 | 75,000 | |
| Nov 25 2014 | ACTC | Ocata Therapeutics ... | Jooste H Le Roux | Chief Commercial Of ... | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Oct 01 2014 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 18,500 | 16 K to 18.5 K (+15.63 %) |
| Oct 01 2014 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 1,250 | 0 | 46,000 | 44.8 K to 46 K (+2.79 %) |
| Oct 01 2014 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 1,250 | 0 | 15,167 | 13.9 K to 15.2 K (+8.98 %) |
| Oct 01 2014 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 1,250 | 0 | 15,584 | 14.3 K to 15.6 K (+8.72 %) |
| Oct 01 2014 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 1,250 | 0 | 203,858 | 202.6 K to 203.9 K (+0.62 %) |
| Sep 26 2014 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 7.94 | 100,000 | 794,000 | 100,000 | |
| Sep 16 2014 | ACTC | Ocata Therapeutics ... | Anglade Eddy | EVP of Clinical Dev ... | Option Exercise | A | 8.49 | 112,000 | 950,880 | 212,000 | |
| Sep 16 2014 | ACTC | Ocata Therapeutics ... | Anglade Eddy | EVP of Clinical Dev ... | Grant | A | 0.00 | 56,000 | 0 | 56,000 | 0 to 56 K |
| Sep 16 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | A | 8.49 | 112,000 | 950,880 | 124,858 | |
| Sep 16 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 56,000 | 0 | 231,509 | 175.5 K to 231.5 K (+31.91 %) |
| Sep 16 2014 | ACTC | Ocata Therapeutics ... | Myles Edward H | COO and CFO | Option Exercise | A | 8.49 | 112,000 | 950,880 | 252,000 | |
| Sep 16 2014 | ACTC | Ocata Therapeutics ... | Myles Edward H | COO and CFO | Grant | A | 0.00 | 56,000 | 0 | 56,000 | 0 to 56 K |
| Sep 11 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 12.57 | 3,930 | 49,400 | 175,509 | 179.4 K to 175.5 K (-2.19 %) |
| Sep 11 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 12.50 | 5,000 | 62,500 | 179,439 | 184.4 K to 179.4 K (-2.71 %) |
| Sep 09 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 10.07 | 10,000 | 100,700 | 184,439 | 194.4 K to 184.4 K (-5.14 %) |
| Sep 09 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 10.00 | 5,000 | 50,000 | 194,439 | 199.4 K to 194.4 K (-2.51 %) |
| Sep 04 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 9.00 | 10,000 | 90,000 | 199,439 | 209.4 K to 199.4 K (-4.77 %) |
| Sep 04 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 9.01 | 5,000 | 45,050 | 209,439 | 214.4 K to 209.4 K (-2.33 %) |
| Sep 04 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 8.12 | 10,000 | 81,200 | 214,439 | 224.4 K to 214.4 K (-4.46 %) |
| Jul 31 2014 | ACTC | Ocata Therapeutics ... | Wotton Paul K | President and CEO | Option Exercise | A | 0.07 | 30,000,000 | 1,965,000 | 30,000,000 | |
| Jul 31 2014 | ACTC | Ocata Therapeutics ... | Wotton Paul K | President and CEO | Grant | A | 0.00 | 30,000,000 | 0 | 30,000,000 | 0 to 30 M |
| Jul 07 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 745,000 | 59,600 | 22,443,822 | 23.2 M to 22.4 M (-3.21 %) |
| Jul 07 2014 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.08 | 755,000 | 60,400 | 23,188,822 | 23.9 M to 23.2 M (-3.15 %) |
| Jul 02 2014 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 1,391,667 | 1.3 M to 1.4 M (+9.87 %) |
| Jul 02 2014 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 4,475,000 | 4.4 M to 4.5 M (+2.87 %) |
| Jul 02 2014 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 1,433,333 | 1.3 M to 1.4 M (+9.55 %) |
| Jul 02 2014 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 125,139 | 0 | 20,260,736 | 20.1 M to 20.3 M (+0.62 %) |
| Jul 02 2014 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 250,000 | 0 | 1,600,000 | 1.4 M to 1.6 M (+18.52 %) |
| Apr 02 2014 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 250,000 | 0 | 1,350,000 | 1.1 M to 1.4 M (+22.73 %) |
| Apr 02 2014 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 4,350,000 | 4.2 M to 4.4 M (+2.96 %) |
| Apr 02 2014 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 1,308,333 | 1.2 M to 1.3 M (+10.56 %) |
| Apr 02 2014 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 1,266,667 | 1.1 M to 1.3 M (+10.95 %) |
| Apr 02 2014 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 597,687 | 0 | 20,135,597 | 19.5 M to 20.1 M (+3.06 %) |
| Feb 06 2014 | ACTC | Ocata Therapeutics ... | Anglade Eddy | EVP of Clinical Dev ... | Option Exercise | A | 0.09 | 10,000,000 | 899,000 | 10,000,000 | |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 0.06 | 1,000,000 | 61,700 | 1,000,000 | |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 250,000 | 0 | 1,100,000 | 850 K to 1.1 M (+29.41 %) |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Option Exercise | A | 0.06 | 500,000 | 30,850 | 500,000 | |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | LANGER ROBERT | Director | Grant | A | 0.00 | 125,000 | 0 | 4,225,000 | 4.1 M to 4.2 M (+3.05 %) |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Option Exercise | A | 0.06 | 500,000 | 30,850 | 500,000 | |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | LOSHITZER ZOHAR | Director | Grant | A | 0.00 | 125,000 | 0 | 1,183,333 | 1.1 M to 1.2 M (+11.81 %) |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Option Exercise | A | 0.06 | 500,000 | 30,850 | 500,000 | |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | PERRY GREGORY D | Director | Grant | A | 0.00 | 125,000 | 0 | 1,141,667 | 1 M to 1.1 M (+12.30 %) |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Option Exercise | A | 0.06 | 500,000 | 30,850 | 500,000 | |
| Jan 03 2014 | ACTC | Ocata Therapeutics ... | SHAPIRO ALAN C | Director | Grant | A | 0.00 | 704,368 | 0 | 19,537,910 | 18.8 M to 19.5 M (+3.74 %) |